Revolution Medicines (RVMD) Accumulated Expenses (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Accumulated Expenses of $192.5 million for Q1 2026, up 96.15% year-over-year from $98.1 million in Q1 2025, and up 230.72% quarter-over-quarter from $58.2 million in Q4 2025.
Revolution Medicines (RVMD) Accumulated Expenses (2019 - 2026) Analysis & Trends
Revolution Medicines' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $192.5 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 96.15% year-over-year to $192.5 million; the TTM figure through Mar 2026 stood at $192.5 million (up 96.15% YoY), while the FY2025 annual figure was $58.2 million, down 39.77% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $192.5 million, up from $58.2 million in the prior quarter.
- The five-year high for Accumulated Expenses was $192.5 million in Q1 2026, with the low at $4.2 million in Q1 2022.
- The 5-year median for Accumulated Expenses is $53.2 million (2024), against an average of $63.1 million.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses sank 79.21% in 2022, then surged 810.37% in 2024.
- Revolution Medicines' Accumulated Expenses stood at $29.4 million in 2022, then jumped by 153.66% to $74.7 million in 2023, then climbed by 29.35% to $96.6 million in 2024, then sank by 39.77% to $58.2 million in 2025, then surged by 230.72% to $192.5 million in 2026.
- Business Quant data shows RVMD's Accumulated Expenses at $192.5 million in Q1 2026, $58.2 million in Q4 2025, and $154.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248.89 Mn |
| Mar 31, 2026 | 192.45 Mn |
| Dec 31, 2025 | 58.19 Mn |
| Sep 30, 2025 | 154.45 Mn |
| Jun 30, 2025 | 114.69 Mn |
| Mar 31, 2025 | 98.11 Mn |
| Dec 31, 2024 | 96.62 Mn |
| Sep 30, 2024 | 78.01 Mn |
| Jun 30, 2024 | 14.73 Mn |
| Mar 31, 2024 | 53.18 Mn |
| Dec 31, 2023 | 74.69 Mn |
| Sep 30, 2023 | 12.83 Mn |
| Jun 30, 2023 | 42.56 Mn |
| Mar 31, 2023 | 5.84 Mn |
| Dec 31, 2022 | 29.45 Mn |
| Sep 30, 2022 | 8.93 Mn |
| Jun 30, 2022 | 33.76 Mn |
| Mar 31, 2022 | 4.25 Mn |
| Dec 31, 2021 | 27.72 Mn |
| Sep 30, 2021 | 23.78 Mn |